Nvidia Says New Platform Could Lift Inference Throughput 30-Fold
Nvidia says Vera Rubin NVL72 delivers up to 30 times the inference throughput per unit cost of GB300 NVL72, while per-GPU HBM capacity increases by about 3%. [[fact-qgiongr82]] Texas governor-elect Gina Hinojosa said she could work with Musk and his companies under Texas conditions, but that current data-center construction must stop until safety measures are found. [[fact-g1po71ojg]] Airbnb reported third-quarter revenue of $4.87 billion, up 19% year over year. [[fact-10nzu4tx1]] Cloudflare expects full-year adjusted earnings per share of $1.35, above its previous forecast. [[fact-m4bawgocg]]
Moderna forecasts 15% to 25% 2026 revenue growth as it targets $8.1B to $8.3B year-end cash
Moderna generated $1.3 billion in third-quarter revenue, up 29% year over year. [[fact:fact-gwgwxjdlw]]The available fact covers quarterly revenue and does not verify the 2026 revenue-growth forecast or year-end cash target in the headline. [[fact:fact-gwgwxjdlw]]
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls - Zacks Investment Research
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls - Zacks Investment Research(摘要待生成)
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock? - Zacks Investment Research
MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock? - Zacks Investment Research(摘要待生成)
Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology - Zacks Investment Research
Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology - Zacks Investment Research(摘要待生成)
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell? - Zacks Investment Research
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell? - Zacks Investment Research(摘要待生成)
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises - Zacks Investment Research
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises - Zacks Investment Research(摘要待生成)
Moderna (MRNA) Q3 Earnings and Revenues Top Estimates - Zacks Investment Research
Moderna (MRNA) Q3 Earnings and Revenues Top Estimates - Zacks Investment Research(摘要待生成)
Moderna Inc (MRNA) Q3 2026 Earnings Call Highlights: Revenue Surges 29% as Guidance Raised and ... - Yahoo Finance
Moderna Inc (MRNA) Q3 2026 Earnings Call Highlights: Revenue Surges 29% as Guidance Raised and ... - Yahoo Finance(摘要待生成)
Moderna, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Moderna, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance(摘要待生成)
Moderna Turns a Profit as R&D Spending Falls: Rapid Earnings Reaction - Yahoo Finance
Moderna earned $162 million in the third quarter, compared with a $200 million loss a year earlier. [[fact:fact-uz8vp4xtt]] Revenue was about $1.3 billion, up 29% from about $1.0 billion. [[fact:fact-p0mu3w6n3]] GAAP diluted EPS was $0.38, versus a loss of $0.51 per share a year earlier. [[fact:fact-z5n7u0ttk]] Research and development expense was $583 million, down 27% from a year earlier. [[fact:fact-gtaat78q1]] Moderna raised its 2026 revenue growth outlook to 15% to 25%, from up to 10%. [[fact:fact-ksu5tkfnl]] The company still lost about $2 billion over the first nine months. [[fact:fact-bkuvob0p0]]
Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts.
Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts.(摘要待生成)
Moderna: Q3 Earnings Snapshot - Yahoo Finance
Moderna: Q3 Earnings Snapshot - Yahoo Finance(摘要待生成)
Moderna Reports Third-Quarter Revenue Growth and Returns to Profit
Moderna reported third-quarter revenue of $1.3 billion, up 29% year over year. [[fact:fact-23emzfob5]] The company reported net income of $162 million, compared with a net loss of $200 million in the year-earlier quarter. [[fact:fact-ojtrbzies]] Diluted earnings per share were $0.38, compared with a loss of $0.51 a year earlier. [[fact:fact-f1lou0udv]]
Can Moderna's First Cancer Therapy Win FDA Approval in 2027? - Zacks Investment Research
Can Moderna's First Cancer Therapy Win FDA Approval in 2027? - Zacks Investment Research(摘要待生成)
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
In the 12 months ended September 30, 2026, Axsome Therapeutics generated about $865.3 million in revenue, approximately 54% higher than in the prior period. [[fact-d86izuc14]] Axsome reported a net loss of around $157.3 million over that period. [[fact-b7k7bi2es]] Moderna generated about $2.5 billion in revenue in the 12 months ended September 30, 2026, growing approximately 13.7% over the prior period. [[fact-us2dnf34c]] Moderna recorded a net loss of around $2.8 billion over that period. [[fact-ith9wk6ky]] The article's author considers Axsome the better buy for 2027, citing Moderna's premium valuation and Axsome's revenue growth. [[fact-5htr1lyal]]
Dow Jones Top Company Headlines at 7 PM ET: Tesla's Polarizing Cybertruck to Wind Down Production Amid Slow Sales | Moderna ...
Dow Jones Top Company Headlines at 7 PM ET: Tesla's Polarizing Cybertruck to Wind Down Production Amid Slow Sales | Moderna ...(摘要待生成)
Moderna president Stephen Hoge sells $11.7M in common stock
Moderna president Stephen Hoge sells $11.7M in common stock(摘要待生成)
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
Moderna reported nearly $1.3 billion in third-quarter revenue, up from just under $1 billion a year earlier. [[fact:fact-a65l5pgd6]] COVID-related revenue accounted for 98% of its top line, with the remainder from its RSV vaccine. [[fact:fact-97787o4pv]] Updated guidance calls for full-year revenue growth of 15% to 25%. [[fact:fact-fdxwr4cdz]] The article's author says Moderna shares are not a buy at the current valuation and are a very risky holding. [[fact:fact-a5ixis9hy]]
莫德纳上调 2026 年业绩预期,CEO 称新款疫苗市场接受度不断提升
莫德纳上调 2026 年业绩预期,CEO 称新款疫苗市场接受度不断提升(摘要待生成)
Moderna在季度业绩发布前市值突破1000亿美元 股价涨幅达9.5%
Moderna在季度业绩发布前市值突破1000亿美元 股价涨幅达9.5%(摘要待生成)
美10月核心CPI超预期 加息预期增加?莫德纳两年来首季盈利!Anthropic顶压冲刺IPO丨20261111从华尔街到陆家嘴
美10月核心CPI超预期 加息预期增加?莫德纳两年来首季盈利!Anthropic顶压冲刺IPO丨20261111从华尔街到陆家嘴(摘要待生成)
Moderna把"人力规划"改成"工作规划",组织变革走到了哪一步
Moderna把"人力规划"改成"工作规划",组织变革走到了哪一步(摘要待生成)